Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13137785 | 1.00 | CARM1 (0.54) | CARM1PRMT6PRMT8CA12CA1 | |
| SCHEMBL10192177 | 0.98 | CARM1 (0.56) | CARM1PRMT6PRMT8CA12CA1 | |
| SCHEMBL19961023 | 0.93 | CARM1 (0.50) | CARM1PRMT6PRMT8CA12CA1 | |
| SCHEMBL23922127 | 0.88 | CACNA1H (0.49) | CARM1PRMT6PRMT8CACNA1HMEN1 | |
| SCHEMBL12257623 | 0.87 | HRH3 (0.50) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL5833206 | 0.85 | HRH3 (0.54) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL10259141 | 0.84 | CARM1 (0.46) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL13762258 | 0.83 | HRH3 (0.50) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL20314580 | 0.82 | CACNA1H (0.43) | CARM1PRMT6PRMT8CACNA1HMEN1 | |
| SCHEMBL7745202 | 0.82 | CACNA1H (0.45) | CARM1PRMT6PRMT8CACNA1HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230123334-A1 | AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-11220486-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) | 2022-01-11 | — | — | US | disclosed |
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2021-08-10 | — | — | US | disclosed |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-12-10 | — | — | US | disclosed |
| US-20200290977-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY | 2020-09-17 | — | — | US | disclosed |
| US-20200190042-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | ALUDA PHARMACEUTICALS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10626094-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC (US) | 2007-03-08 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | CARM1 3178/4885PRMT6 1629/4885PRMT8 1860/4885 |
| US-11220486-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | ACP1, PTPRCAP, PTPA | CARM1 2970/4885PRMT6 1628/4885PRMT8 1015/4885 |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | AHR, HCAR2, HCAR1 | CARM1 3087/4885PRMT6 3140/4885PRMT8 3267/4885 |
| US-10626094-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | ACP1, PTPRCAP, PTPA | CARM1 2970/4885PRMT6 1628/4885PRMT8 1015/4885 |
| US-20200290977-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | ACP1, PTPRCAP, PTPA | CARM1 2970/4885PRMT6 1628/4885PRMT8 1015/4885 |
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | PSMC1, PSME3, PSMB1 | CARM1 2232/4885PRMT6 2488/4885PRMT8 2812/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CARM1 3887/4885PRMT6 1456/4885PRMT8 1766/4885 |
| US-20200190042-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | VIM, HASPIN, WASF2 | CARM1 1731/4885PRMT6 1546/4885PRMT8 2007/4885 |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | PSMC1, PSME3, PSMB1 | CARM1 2232/4885PRMT6 2488/4885PRMT8 2812/4885 |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | KEAP1, GOT2, COL1A1 | CARM1 1397/4885PRMT6 567/4885PRMT8 1443/4885 |
| US-20080058383-A1 | Androgen Receptor Modulators | NR5A1, ESRRA, AR | CARM1 1717/4885PRMT6 668/4885PRMT8 817/4885 |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | AR, SHBG, NR5A1 | CARM1 776/4885PRMT6 1526/4885PRMT8 1763/4885 |
| US-20230123334-A1 | AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CETP, PLIN1, NOTUM | CARM1 2798/4885PRMT6 790/4885PRMT8 320/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | CARM1 1908/4885PRMT6 2154/4885PRMT8 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.